Vitamin D in Prostate Cancer

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) is driven by androgen receptor (AR) activation.
• Calcitriol (vitamin D3 metabolite) shows inhibitory effects on prostate cancer in preclinical studies.
• Clinical trials with calcitriol have yielded inconclusive results, but recent pilot studies show promise for vitamin D3 supplementation.

Purpose of the Study:

• To explore the mechanisms of vitamin D in inhibiting prostate cancer.
• To investigate the cross-talk between androgen receptor (AR) and vitamin D receptor (VDR) pathways.
• To identify potential therapeutic strategies for prostate cancer leveraging vitamin D.

Main Methods:

• Review of cell culture and animal studies on vitamin D's effects.
• Analysis of gene expression changes mediated by the vitamin D receptor (VDR).
• Examination of AR-VDR cross-talk in modulating androgen metabolism.

Main Results:

• Vitamin D inhibits prostate cancer cell proliferation via cell cycle arrest, apoptosis, and altered gene expression.
• Vitamin D influences angiogenesis and cell migration.
• AR-VDR cross-talk affects androgen metabolism; vitamin D promotes androgen inactivation, while androgen inhibits calcitriol-degrading enzyme (CYP24A1).
• Key enzymes like CYP3A4 and SULT2B1b are reduced, and CYP24A1 is overexpressed in advanced prostate cancer.

Conclusions:

• Vitamin D exhibits multifaceted anti-prostate cancer mechanisms.
• Understanding AR-VDR interactions is crucial for prostate cancer treatment.
• Future strategies may involve combining novel calcitriol analogs with CYP24A1 inhibitors or other agents for enhanced efficacy.